Sanius Health acquires Cambridge digital therapy platform THERAPYAUDIT, expanding AI infrastructure across 35+ NHS hospitals

Sanius Health, the London-based AI and patient data platform, has acquired Cambridge cancer digital health company THERAPYAUDIT, developer of the beetroot therapy audit care platform used by NHS clinicians to monitor treatments, track outcomes and coordinate complex cancer and care pathways.

The acquisition expands the reach of Sanius Health technology to more than 35 NHS hospitals, strengthening the company’s ability to support clinicians managing complex diseases including oncology, haematology, rare diseases and advanced therapies. The transaction was completed for an undisclosed cash consideration.

By integrating THERAPYAUDIT into the Sanius platform, hospitals gain access to a broader digital infrastructure designed to improve care coordination, provide earlier clinical insight and support safer management of patients living with complex conditions.

Orlando Agrippa, founder and CEO of Sanius Health, said: “Healthcare is entering a new era where data, AI and real world evidence will shape how we deliver care and develop new treatments.

“THERAPYAUDIT has built an excellent platform used by clinicians across the NHS to monitor therapies and manage complex treatment pathways.

“By bringing this technology into Sanius we can combine therapy oversight with AI driven predictive insight and large scale patient registries.

“The result is a more intelligent system for managing disease, improving outcomes for patients and accelerating research.

“Expanding our footprint across more than thirty five NHS hospitals strengthens our partnerships with the NHS and creates a powerful platform for clinical innovation, advanced therapies and next generation research.”

For patients and families, the combined platform means earlier identification of complications, better coordination across specialist teams and improved access to innovative treatments and clinical trials.

As treatment pathways become more personalised and complex, the ability to monitor therapies and outcomes in real time becomes critical for both patient safety and long term care management.

THERAPYAUDIT has built a strong reputation within the NHS through its beetroot therapy audit platform, which enables clinicians to track therapy delivery, measure outcomes and coordinate care across multidisciplinary teams.

The system is already used by a number of leading NHS organisations including Cambridge University Hospitals NHS Foundation Trust, Royal Papworth Hospital NHS Foundation Trust, University Hospitals Birmingham NHS Foundation Trust, Guy’s and St Thomas’ NHS Foundation Trust and Leeds Teaching Hospitals NHS Trust, among others.

Bringing THERAPYAUDIT into the Sanius ecosystem allows these therapy monitoring capabilities to be combined with AI driven predictive analytics, longitudinal disease registries and real world data infrastructure, creating a more connected platform for managing complex diseases.

The integration will also expand the research capabilities available to clinicians and life sciences partners.

By linking therapy pathway data with structured disease registries and longitudinal patient monitoring, the combined platform will generate deeper real world insight into how treatments perform in routine clinical practice.

This is increasingly important as advanced therapies, biologics and precision medicines move into mainstream clinical use.

Real world evidence generated through digital registries and therapy monitoring platforms helps clinicians, regulators and pharmaceutical companies understand how treatments perform outside controlled clinical trials, accelerating research and improving long term patient outcomes.

The acquisition also strengthens Sanius Health’s presence within the UK’s life sciences ecosystem.

With THERAPYAUDIT based in Cambridge, one of Europe’s leading centres for biomedical research and innovation, the transaction expands Sanius Health’s footprint across the UK’s research corridor linking London, Cambridge and Oxford.

The combined platform will support further investment in AI enabled care coordination, predictive clinical insight and digital infrastructure designed to help healthcare systems manage growing patient demand and increasingly complex treatment pathways.

Chris Wright, founder of THERAPYAUDIT, said: “We’re delighted to welcome Sanius Health as our new co-owner. Sanius and THERAPYAUDIT share the same ambition in digital health, pushing the boundaries of technology development and deployment to enhance patient care while improving efficiency across healthcare systems.

“Working together the two companies will expand partnerships and explore new specialties that can benefit from the beetroot platform alongside the Sanius Health AI and data infrastructure.

“The combination creates a powerful opportunity to support clinicians, improve patient pathways and accelerate innovation across multiple therapeutic areas.”

As healthcare systems adopt more personalised therapies and patients live longer with complex conditions, the need for connected digital infrastructure that links care delivery, patient monitoring and research continues to grow.

The integration of THERAPYAUDIT into the Sanius platform is designed to meet that need.